NCT01785758View on ClinicalTrials.gov

Efficacy and Safety of Sugammadex in Renal Diseased Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Kidney Failure, ChronicNeuromuscular Blockade
Interventions
DRUG

Sugammadex (4 mg/Kg)

Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium

Trial Locations (1)

04038002

Hospital do Rim e Hipertensão - Fundação Oswaldo Ramos, São Paulo

All Listed Sponsors
collaborator

Hospital General Universitario Santa Lucía

OTHER

lead

Federal University of São Paulo

OTHER

NCT01785758 - Efficacy and Safety of Sugammadex in Renal Diseased Patients | Biotech Hunter | Biotech Hunter